Lehtonen A, Himanen P, Saraste M, Niittymäki K, Marniemi J
Br J Clin Pharmacol. 1986;21 Suppl 1(Suppl 1):77S-81S. doi: 10.1111/j.1365-2125.1986.tb02857.x.
The effects on plasma lipids and apoproteins A-I and B of oral administration of doxazosin and atenolol over a 20-week period were studied in 42 patients with mild to moderate essential hypertension. Total plasma cholesterol decreased by 8.9% (P less than 0.01) and LDL cholesterol by 16.9% (P less than 0.01) after 20 weeks' treatment with doxazosin. Total HDL cholesterol and HDL2 cholesterol concentrations increased slightly during doxazosin treatment and the increase in HDL2 level at 4 weeks was statistically significant (P less than 0.05). At 20 weeks, the levels of total HDL cholesterol and HDL2 were significantly (P less than 0.05) lower with atenolol than with doxazosin. The ratio HDL/total cholesterol increased during doxazosin treatment (P less than 0.05 at 4, 12 and 20 weeks). The HDL/total cholesterol ratio was significantly higher after 20 weeks with doxazosin than with atenolol (P less than 0.05). The levels of VLDL cholesterol and triglycerides increased significantly (P less than 0.01) during atenolol treatment. The concentrations of apoproteins A-I and B did not change significantly during treatment with doxazosin or with atenolol but at 20 weeks the ratio of apo A-I to apo B was significantly (P less than 0.05) lower with atenolol than with doxazosin. On the basis of these results, doxazosin would seem to have significant favourable effects on the serum lipid profile.
在42例轻至中度原发性高血压患者中,研究了口服多沙唑嗪和阿替洛尔20周对血浆脂质及载脂蛋白A-I和B的影响。多沙唑嗪治疗20周后,血浆总胆固醇下降了8.9%(P<0.01),低密度脂蛋白胆固醇下降了16.9%(P<0.01)。在多沙唑嗪治疗期间,高密度脂蛋白总胆固醇和高密度脂蛋白2胆固醇浓度略有升高,4周时高密度脂蛋白2水平的升高具有统计学意义(P<0.05)。在20周时,阿替洛尔治疗组的高密度脂蛋白总胆固醇和高密度脂蛋白2水平显著低于多沙唑嗪治疗组(P<0.05)。多沙唑嗪治疗期间高密度脂蛋白/总胆固醇比值升高(4周、12周和20周时P<0.05)。20周后,多沙唑嗪治疗组的高密度脂蛋白/总胆固醇比值显著高于阿替洛尔治疗组(P<0.05)。阿替洛尔治疗期间,极低密度脂蛋白胆固醇和甘油三酯水平显著升高(P<0.01)。多沙唑嗪或阿替洛尔治疗期间,载脂蛋白A-I和B的浓度无显著变化,但在20周时,阿替洛尔治疗组的载脂蛋白A-I与载脂蛋白B的比值显著低于多沙唑嗪治疗组(P<0.05)。基于这些结果,多沙唑嗪似乎对血清脂质谱有显著的有利影响。